 | • レポートコード：D005-12961 • 出版社/出版日：GlobalInfoResearch / 2020年5月28日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール • 産業分類：医療・製薬 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、呼吸器薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。呼吸器薬の種類別市場規模（吸入コルチコステロイド、長時間作用型ベータ2アゴニスト、抗ヒスタミン剤、血管拡張剤、その他）、用途別市場規模（喘息・COPD、アレルギー性鼻炎、肺高血圧症、嚢胞性線維症、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：Sanofi SA、Zambon Company S.p.A、AstraZeneca Plc.、Meda Pharmaceuticals、Cheisi Farmaceutici S.p.A、Circassia Pharmaceuticals Plc.、Merck Sharp & Dohme Limited、Mallinckrodt Pharmaceuticals Plc.、GlaxoSmithKline Plc.、Alaxia SAS ・地域別グローバル市場分析 2015年-2020年 ・呼吸器薬の北米市場（アメリカ、カナダ、メキシコ） ・呼吸器薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・呼吸器薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・呼吸器薬の南米市場（ブラジル、アルゼンチン） ・呼吸器薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：吸入コルチコステロイド、長時間作用型ベータ2アゴニスト、抗ヒスタミン剤、血管拡張剤、その他 ・用途別分析：喘息・COPD、アレルギー性鼻炎、肺高血圧症、嚢胞性線維症、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Pulmonary Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.4% in the forecast period of 2020 to 2025 and will expected to reach USD 58240 million by 2025, from USD 50920 million in 2019.
The Pulmonary Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Pulmonary Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Pulmonary Drugs market has been segmented into
Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Others
By Application, Pulmonary Drugs has been segmented into:
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Pulmonary Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Pulmonary Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Pulmonary Drugs market.
The report offers in-depth assessment of the growth and other aspects of the Pulmonary Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Pulmonary Drugs Market Share Analysis
Pulmonary Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Pulmonary Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Pulmonary Drugs sales, revenue and market share for each player covered in this report.
The major players covered in Pulmonary Drugs are:
Sanofi SA
Zambon Company S.p.A
AstraZeneca Plc.
Meda Pharmaceuticals
Cheisi Farmaceutici S.p.A
Circassia Pharmaceuticals Plc.
Merck Sharp & Dohme Limited
Mallinckrodt Pharmaceuticals Plc.
GlaxoSmithKline Plc.
Alaxia SAS
Among other players domestic and global, Pulmonary Drugs market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Pulmonary Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Pulmonary Drugs, with price, sales, revenue and global market share of Pulmonary Drugs in 2018 and 2019.
Chapter 3, the Pulmonary Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Pulmonary Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Pulmonary Drugs market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Pulmonary Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Pulmonary Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Pulmonary Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Inhaled Corticosteroids
1.2.3 Long Acting Beta-2 Agonists
1.2.4 Antihistamines
1.2.5 Vasodilators
1.2.6 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Pulmonary Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Asthma & COPD
1.3.3 Allergic Rhinitis
1.3.4 Pulmonary Arterial Hypertension
1.3.5 Cystic Fibrosis
1.3.6 Others
1.4 Overview of Global Pulmonary Drugs Market
1.4.1 Global Pulmonary Drugs Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Sanofi SA
2.1.1 Sanofi SA Details
2.1.2 Sanofi SA Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Sanofi SA SWOT Analysis
2.1.4 Sanofi SA Product and Services
2.1.5 Sanofi SA Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Zambon Company S.p.A
2.2.1 Zambon Company S.p.A Details
2.2.2 Zambon Company S.p.A Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Zambon Company S.p.A SWOT Analysis
2.2.4 Zambon Company S.p.A Product and Services
2.2.5 Zambon Company S.p.A Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 AstraZeneca Plc.
2.3.1 AstraZeneca Plc. Details
2.3.2 AstraZeneca Plc. Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 AstraZeneca Plc. SWOT Analysis
2.3.4 AstraZeneca Plc. Product and Services
2.3.5 AstraZeneca Plc. Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Meda Pharmaceuticals
2.4.1 Meda Pharmaceuticals Details
2.4.2 Meda Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Meda Pharmaceuticals SWOT Analysis
2.4.4 Meda Pharmaceuticals Product and Services
2.4.5 Meda Pharmaceuticals Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Cheisi Farmaceutici S.p.A
2.5.1 Cheisi Farmaceutici S.p.A Details
2.5.2 Cheisi Farmaceutici S.p.A Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Cheisi Farmaceutici S.p.A SWOT Analysis
2.5.4 Cheisi Farmaceutici S.p.A Product and Services
2.5.5 Cheisi Farmaceutici S.p.A Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Circassia Pharmaceuticals Plc.
2.6.1 Circassia Pharmaceuticals Plc. Details
2.6.2 Circassia Pharmaceuticals Plc. Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Circassia Pharmaceuticals Plc. SWOT Analysis
2.6.4 Circassia Pharmaceuticals Plc. Product and Services
2.6.5 Circassia Pharmaceuticals Plc. Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Merck Sharp & Dohme Limited
2.7.1 Merck Sharp & Dohme Limited Details
2.7.2 Merck Sharp & Dohme Limited Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Merck Sharp & Dohme Limited SWOT Analysis
2.7.4 Merck Sharp & Dohme Limited Product and Services
2.7.5 Merck Sharp & Dohme Limited Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Mallinckrodt Pharmaceuticals Plc.
2.8.1 Mallinckrodt Pharmaceuticals Plc. Details
2.8.2 Mallinckrodt Pharmaceuticals Plc. Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Mallinckrodt Pharmaceuticals Plc. SWOT Analysis
2.8.4 Mallinckrodt Pharmaceuticals Plc. Product and Services
2.8.5 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 GlaxoSmithKline Plc.
2.9.1 GlaxoSmithKline Plc. Details
2.9.2 GlaxoSmithKline Plc. Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 GlaxoSmithKline Plc. SWOT Analysis
2.9.4 GlaxoSmithKline Plc. Product and Services
2.9.5 GlaxoSmithKline Plc. Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Alaxia SAS
2.10.1 Alaxia SAS Details
2.10.2 Alaxia SAS Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Alaxia SAS SWOT Analysis
2.10.4 Alaxia SAS Product and Services
2.10.5 Alaxia SAS Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Pulmonary Drugs Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Pulmonary Drugs Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Pulmonary Drugs Manufacturer Market Share in 2019
3.3.2 Top 6 Pulmonary Drugs Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Pulmonary Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Pulmonary Drugs Sales and Market Share by Regions (2015-2020)
4.1.2 Global Pulmonary Drugs Revenue and Market Share by Regions (2015-2020)
4.2 North America Pulmonary Drugs Sales and Growth Rate (2015-2020)
4.3 Europe Pulmonary Drugs Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Pulmonary Drugs Sales and Growth Rate (2015-2020)
4.5 South America Pulmonary Drugs Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Pulmonary Drugs Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Pulmonary Drugs Sales, Revenue and Market Share by Country
5.1.1 North America Pulmonary Drugs Sales and Market Share by Country (2015-2020)
5.1.2 North America Pulmonary Drugs Revenue and Market Share by Country (2015-2020)
5.2 United States Pulmonary Drugs Sales and Growth Rate (2015-2020)
5.3 Canada Pulmonary Drugs Sales and Growth Rate (2015-2020)
5.4 Mexico Pulmonary Drugs Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Pulmonary Drugs Sales, Revenue and Market Share by Country
6.1.1 Europe Pulmonary Drugs Sales and Market Share by Country (2015-2020)
6.1.2 Europe Pulmonary Drugs Revenue and Market Share by Country (2015-2020)
6.2 Germany Pulmonary Drugs Sales and Growth Rate (2015-2020)
6.3 UK Pulmonary Drugs Sales and Growth Rate (2015-2020)
6.4 France Pulmonary Drugs Sales and Growth Rate (2015-2020)
6.5 Russia Pulmonary Drugs Sales and Growth Rate (2015-2020)
6.6 Italy Pulmonary Drugs Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Pulmonary Drugs Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Pulmonary Drugs Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Pulmonary Drugs Revenue and Market Share by Regions (2015-2020)
7.2 China Pulmonary Drugs Sales and Growth Rate (2015-2020)
7.3 Japan Pulmonary Drugs Sales and Growth Rate (2015-2020)
7.4 Korea Pulmonary Drugs Sales and Growth Rate (2015-2020)
7.5 India Pulmonary Drugs Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Pulmonary Drugs Sales and Growth Rate (2015-2020)
7.7 Australia Pulmonary Drugs Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Pulmonary Drugs Sales, Revenue and Market Share by Country
8.1.1 South America Pulmonary Drugs Sales and Market Share by Country (2015-2020)
8.1.2 South America Pulmonary Drugs Revenue and Market Share by Country (2015-2020)
8.2 Brazil Pulmonary Drugs Sales and Growth Rate (2015-2020)
8.3 Argentina Pulmonary Drugs Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Pulmonary Drugs Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Pulmonary Drugs Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Pulmonary Drugs Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Pulmonary Drugs Sales and Growth Rate (2015-2020)
9.3 Turkey Pulmonary Drugs Sales and Growth Rate (2015-2020)
9.4 Egypt Pulmonary Drugs Sales and Growth Rate (2015-2020)
9.5 South Africa Pulmonary Drugs Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Pulmonary Drugs Sales and Market Share by Type (2015-2020)
10.2 Global Pulmonary Drugs Revenue and Market Share by Type (2015-2020)
10.3 Global Pulmonary Drugs Price by Type (2015-2020)
11 Global Pulmonary Drugs Market Segment by Application
11.1 Global Pulmonary Drugs Sales Market Share by Application (2015-2020)
11.2 Global Pulmonary Drugs Revenue Market Share by Application (2015-2020)
11.3 Global Pulmonary Drugs Price by Application (2015-2020)
12 Market Forecast
12.1 Global Pulmonary Drugs Sales, Revenue and Growth Rate (2021-2025)
12.2 Pulmonary Drugs Market Forecast by Regions (2021-2025)
12.2.1 North America Pulmonary Drugs Market Forecast (2021-2025)
12.2.2 Europe Pulmonary Drugs Market Forecast (2021-2025)
12.2.3 Asia-Pacific Pulmonary Drugs Market Forecast (2021-2025)
12.2.4 South America Pulmonary Drugs Market Forecast (2021-2025)
12.2.5 Middle East & Africa Pulmonary Drugs Market Forecast (2021-2025)
12.3 Pulmonary Drugs Market Forecast by Type (2021-2025)
12.3.1 Global Pulmonary Drugs Sales Forecast by Type (2021-2025)
12.3.2 Global Pulmonary Drugs Market Share Forecast by Type (2021-2025)
12.4 Pulmonary Drugs Market Forecast by Application (2021-2025)
12.4.1 Global Pulmonary Drugs Sales Forecast by Application (2021-2025)
12.4.2 Global Pulmonary Drugs Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Pulmonary Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Pulmonary Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Pulmonary Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Sanofi SA Basic Information, Manufacturing Base and Competitors
Table 8. Sanofi SA Pulmonary Drugs Major Business
Table 9. Sanofi SA Pulmonary Drugs Total Revenue (USD Million) (2017-2018)
Table 10. Sanofi SA SWOT Analysis
Table 11. Sanofi SA Pulmonary Drugs Product and Services
Table 12. Sanofi SA Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Zambon Company S.p.A Basic Information, Manufacturing Base and Competitors
Table 14. Zambon Company S.p.A Pulmonary Drugs Major Business
Table 15. Zambon Company S.p.A Pulmonary Drugs Total Revenue (USD Million) (2017-2018)
Table 16. Zambon Company S.p.A SWOT Analysis
Table 17. Zambon Company S.p.A Pulmonary Drugs Product and Services
Table 18. Zambon Company S.p.A Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. AstraZeneca Plc. Basic Information, Manufacturing Base and Competitors
Table 20. AstraZeneca Plc. Pulmonary Drugs Major Business
Table 21. AstraZeneca Plc. Pulmonary Drugs Total Revenue (USD Million) (2017-2018)
Table 22. AstraZeneca Plc. SWOT Analysis
Table 23. AstraZeneca Plc. Pulmonary Drugs Product and Services
Table 24. AstraZeneca Plc. Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Meda Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 26. Meda Pharmaceuticals Pulmonary Drugs Major Business
Table 27. Meda Pharmaceuticals Pulmonary Drugs Total Revenue (USD Million) (2017-2018)
Table 28. Meda Pharmaceuticals SWOT Analysis
Table 29. Meda Pharmaceuticals Pulmonary Drugs Product and Services
Table 30. Meda Pharmaceuticals Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Cheisi Farmaceutici S.p.A Basic Information, Manufacturing Base and Competitors
Table 32. Cheisi Farmaceutici S.p.A Pulmonary Drugs Major Business
Table 33. Cheisi Farmaceutici S.p.A Pulmonary Drugs Total Revenue (USD Million) (2017-2018)
Table 34. Cheisi Farmaceutici S.p.A SWOT Analysis
Table 35. Cheisi Farmaceutici S.p.A Pulmonary Drugs Product and Services
Table 36. Cheisi Farmaceutici S.p.A Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Circassia Pharmaceuticals Plc. Basic Information, Manufacturing Base and Competitors
Table 38. Circassia Pharmaceuticals Plc. Pulmonary Drugs Major Business
Table 39. Circassia Pharmaceuticals Plc. Pulmonary Drugs Total Revenue (USD Million) (2017-2018)
Table 40. Circassia Pharmaceuticals Plc. SWOT Analysis
Table 41. Circassia Pharmaceuticals Plc. Pulmonary Drugs Product and Services
Table 42. Circassia Pharmaceuticals Plc. Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Merck Sharp & Dohme Limited Basic Information, Manufacturing Base and Competitors
Table 44. Merck Sharp & Dohme Limited Pulmonary Drugs Major Business
Table 45. Merck Sharp & Dohme Limited Pulmonary Drugs Total Revenue (USD Million) (2017-2018)
Table 46. Merck Sharp & Dohme Limited SWOT Analysis
Table 47. Merck Sharp & Dohme Limited Pulmonary Drugs Product and Services
Table 48. Merck Sharp & Dohme Limited Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. Mallinckrodt Pharmaceuticals Plc. Basic Information, Manufacturing Base and Competitors
Table 50. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Major Business
Table 51. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Total Revenue (USD Million) (2017-2018)
Table 52. Mallinckrodt Pharmaceuticals Plc. SWOT Analysis
Table 53. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product and Services
Table 54. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. GlaxoSmithKline Plc. Basic Information, Manufacturing Base and Competitors
Table 56. GlaxoSmithKline Plc. Pulmonary Drugs Major Business
Table 57. GlaxoSmithKline Plc. Pulmonary Drugs Total Revenue (USD Million) (2017-2018)
Table 58. GlaxoSmithKline Plc. SWOT Analysis
Table 59. GlaxoSmithKline Plc. Pulmonary Drugs Product and Services
Table 60. GlaxoSmithKline Plc. Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 61. Alaxia SAS Basic Information, Manufacturing Base and Competitors
Table 62. Alaxia SAS Pulmonary Drugs Major Business
Table 63. Alaxia SAS Pulmonary Drugs Total Revenue (USD Million) (2017-2018)
Table 64. Alaxia SAS SWOT Analysis
Table 65. Alaxia SAS Pulmonary Drugs Product and Services
Table 66. Alaxia SAS Pulmonary Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 67. Global Pulmonary Drugs Sales by Manufacturer (2018-2019) (K Units)
Table 68. Global Pulmonary Drugs Revenue by Manufacturer (2018-2019) (USD Million)
Table 69. Global Pulmonary Drugs Sales by Regions (2015-2020) (K Units)
Table 70. Global Pulmonary Drugs Sales Market Share by Regions (2015-2020)
Table 71. Global Pulmonary Drugs Revenue by Regions (2015-2020) (USD Million)
Table 72. North America Pulmonary Drugs Sales by Countries (2015-2020) (K Units)
Table 73. North America Pulmonary Drugs Sales Market Share by Countries (2015-2020)
Table 74. North America Pulmonary Drugs Revenue by Countries (2015-2020) (USD Million)
Table 75. North America Pulmonary Drugs Revenue Market Share by Countries (2015-2020)
Table 76. Europe Pulmonary Drugs Sales by Countries (2015-2020) (K Units)
Table 77. Europe Pulmonary Drugs Sales Market Share by Countries (2015-2020)
Table 78. Europe Pulmonary Drugs Revenue by Countries (2015-2020) (USD Million)
Table 79. Asia-Pacific Pulmonary Drugs Sales by Regions (2015-2020) (K Units)
Table 80. Asia-Pacific Pulmonary Drugs Sales Market Share by Regions (2015-2020)
Table 81. Asia-Pacific Pulmonary Drugs Revenue by Regions (2015-2020) (USD Million)
Table 82. South America Pulmonary Drugs Sales by Countries (2015-2020) (K Units)
Table 83. South America Pulmonary Drugs Sales Market Share by Countries (2015-2020)
Table 84. South America Pulmonary Drugs Revenue by Countries (2015-2020) (USD Million)
Table 85. South America Pulmonary Drugs Revenue Market Share by Countries (2015-2020)
Table 86. Middle East & Africa Pulmonary Drugs Sales by Countries (2015-2020) (K Units)
Table 87. Middle East & Africa Pulmonary Drugs Sales Market Share by Countries (2015-2020)
Table 88. Middle East & Africa Pulmonary Drugs Revenue by Countries (2015-2020) (USD Million)
Table 89. Middle East & Africa Pulmonary Drugs Revenue Market Share by Countries (2015-2020)
Table 90. Global Pulmonary Drugs Sales by Type (2015-2020) (K Units)
Table 91. Global Pulmonary Drugs Sales Share by Type (2015-2020)
Table 92. Global Pulmonary Drugs Revenue by Type (2015-2020) (USD Million)
Table 93. Global Pulmonary Drugs Revenue Share by Type (2015-2020)
Table 94. Global Pulmonary Drugs Sales by Application (2015-2020) (K Units)
Table 95. Global Pulmonary Drugs Sales Share by Application (2015-2020)
Table 96. Global Pulmonary Drugs Sales Forecast by Regions (2021-2025) (K Units)
Table 97. Global Pulmonary Drugs Market Share Forecast by Regions (2021-2025)
Table 98. Global Pulmonary Drugs Sales Forecast by Type (2021-2025) (K Units)
Table 99. Global Pulmonary Drugs Market Share Forecast by Type (2021-2025)
Table 100. Global Pulmonary Drugs Sales Forecast by Application (2021-2025)
Table 101. Global Pulmonary Drugs Market Share Forecast by Application (2021-2025)
Table 102. Direct Channel Pros & Cons
Table 103. Indirect Channel Pros & Cons
Table 104. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Pulmonary Drugs Picture
Figure 2. Global Sales Market Share of Pulmonary Drugs by Type in 2019
Figure 3. Inhaled Corticosteroids Picture
Figure 4. Long Acting Beta-2 Agonists Picture
Figure 5. Antihistamines Picture
Figure 6. Vasodilators Picture
Figure 7. Others Picture
Figure 8. Pulmonary Drugs Sales Market Share by Application in 2018
Figure 9. Asthma & COPD Picture
Figure 10. Allergic Rhinitis Picture
Figure 11. Pulmonary Arterial Hypertension Picture
Figure 12. Cystic Fibrosis Picture
Figure 13. Others Picture
Figure 14. Global Pulmonary Drugs Market Status and Outlook (2015-2025) (USD Million)
Figure 15. United States Pulmonary Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Canada Pulmonary Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Mexico Pulmonary Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Germany Pulmonary Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 19. France Pulmonary Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 20. UK Pulmonary Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Russia Pulmonary Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Italy Pulmonary Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 23. China Pulmonary Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Japan Pulmonary Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Korea Pulmonary Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 26. India Pulmonary Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Southeast Asia Pulmonary Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Australia Pulmonary Drugs Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 29. Brazil Pulmonary Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Egypt Pulmonary Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 31. Saudi Arabia Pulmonary Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 32. South Africa Pulmonary Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 33. Turkey Pulmonary Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 34. Global Pulmonary Drugs Sales Market Share by Manufacturer in 2019
Figure 35. Global Pulmonary Drugs Revenue Market Share by Manufacturer in 2019
Figure 36. Top 3 Pulmonary Drugs Manufacturer (Revenue) Market Share in 2019
Figure 37. Top 6 Pulmonary Drugs Manufacturer (Revenue) Market Share in 2019
Figure 38. Key Manufacturer Market Share Trend
Figure 39. Global Pulmonary Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 40. Global Pulmonary Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 41. Global Pulmonary Drugs Revenue Market Share by Regions (2015-2020)
Figure 42. Global Pulmonary Drugs Revenue Market Share by Regions in 2018
Figure 43. North America Pulmonary Drugs Sales and Growth Rate (2015-2020)
Figure 44. Europe Pulmonary Drugs Sales and Growth Rate (2015-2020)
Figure 45. Asia-Pacific Pulmonary Drugs Sales and Growth Rate (2015-2020)
Figure 46. South America Pulmonary Drugs Sales and Growth Rate (2015-2020)
Figure 47. Middle East & Africa Pulmonary Drugs Sales and Growth Rate (2015-2020)
Figure 48. North America Pulmonary Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 49. North America Pulmonary Drugs Sales Market Share by Countries (2015-2020)
Figure 50. North America Pulmonary Drugs Sales Market Share by Countries in 2018
Figure 51. North America Pulmonary Drugs Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 52. North America Pulmonary Drugs Revenue Market Share by Countries in 2018
Figure 53. United States Pulmonary Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 54. Canada Pulmonary Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 55. Mexico Pulmonary Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 56. Europe Pulmonary Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 57. Europe Pulmonary Drugs Revenue Market Share by Countries (2015-2020)
Figure 58. Europe Pulmonary Drugs Revenue Market Share by Countries in 2019
Figure 59. Germany Pulmonary Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 60. UK Pulmonary Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 61. France Pulmonary Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 62. Russia Pulmonary Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 63. Italy Pulmonary Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 64. Asia-Pacific Pulmonary Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 65. Asia-Pacific Pulmonary Drugs Sales Market Share by Regions 2019
Figure 66. Asia-Pacific Pulmonary Drugs Revenue Market Share by Regions 2019
Figure 67. China Pulmonary Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 68. Japan Pulmonary Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 69. Korea Pulmonary Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 70. India Pulmonary Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 71. Southeast Asia Pulmonary Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 72. South America Pulmonary Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 73. South America Pulmonary Drugs Sales Market Share by Countries in 2019
Figure 74. South America Pulmonary Drugs Revenue Market Share by Countries in 2019
Figure 75. Brazil Pulmonary Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 76. Argentina Pulmonary Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 77. Middle East and Africa Pulmonary Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 78. Middle East and Africa Pulmonary Drugs Sales Market Share by Countries in 2019
Figure 79. Middle East and Africa Pulmonary Drugs Revenue Market Share by Countries (2015-2020)
Figure 80. Middle East and Africa Pulmonary Drugs Revenue Market Share by Countries in 2019
Figure 81. Saudi Arabia Pulmonary Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 82. Egypt Pulmonary Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 83. Turkey Pulmonary Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 84. South Africa Pulmonary Drugs Sales and Growth Rate (2015-2020) (K Units)
Figure 85. Global Pulmonary Drugs Sales and Growth Rate (2021-2025) (K Units)
Figure 86. Global Pulmonary Drugs Revenue and Growth Rate (2021-2025) (USD Million)
Figure 87. North America Sales Pulmonary Drugs Market Forecast (2021-2025) (K Units)
Figure 88. Europe Sales Pulmonary Drugs Market Forecast (2021-2025) (K Units)
Figure 89. Asia-Pacific Sales Pulmonary Drugs Market Forecast (2021-2025) (K Units)
Figure 90. South America Sales Pulmonary Drugs Market Forecast (2021-2025) (K Units)
Figure 91. Middle East & Africa Sales Pulmonary Drugs Market Forecast (2021-2025) (K Units)
Figure 92. Sales Channel: Direct Channel vs Indirect Channel
経カテーテル肺動脈弁（TPV）の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Transcatheter Pulmonary Valve (TPV) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Transcath…- 特発性肺線維症薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Idiopathic Pulmonary Fibrosis Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Idiopathic…
- バルビツール酸系薬物の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Barbiturate Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Barbiturate Drugs market re…
- エリスロポエチン（EPO）薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Erythropoietin (EPO) Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 5.5% in the forecast period of 2020 to 2025 and will expected to reach USD 10830 million by 2025, from USD 8727.6 million in 2019. The Erythropoi…
- 非ステロイド性抗炎症薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Nonsteroidal Antiinflammatory Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Nonsteroi…